patients with abnormal chest radiograph) were com pared with those of a group of 18 patients with intraocular inflammation due to biopsy-proven sarcoi dosis. The mean follow-up (± SD) was 4.5 ± 3.4 years in the presumed ocular sarcoidosis group and 7.8 ± 5.3 years in the biopsy-proven sarcoidosis group.
progressive pulmonary fibrosis and organ damage. This may be modified but not necessarily prevented by corticosteroid therapy. Granulomata can be distributed throughout the body without causing significant organ dysfunction or may be concentrated in one or more organs with striking clinical effects. 6 Ocular involvement is seen in 25-50% of patients with systemic sarcoidosis3 ,4,8 -1O and can precede involvement of other organs by years?,4 , l0·l1
The diagnosis of sarcoidosis is based on the histological evidence of non-caseating epithelioid cell granulomata, in the presence of supporting clinical and/or radiological findings. In patients with sarcoidosis involving only their eyes, histological diagnosis can be difficult_ There are conflicting reports regarding the sensitivity of conjunctival biopsy2,7, 1 2,13 as intraocular inflammation is not always associated with conjunctival involvement.1 2 Other diagnostic tests for sarcoidosis include serum angiotensin converting enzyme (ACE) levels and gallium scanning.5,14-18 Raised ACE level has been associated with active sarcoidosis and appears to be a sensitive biochemical marker of disease activity ? , S , 1 4,1 6J 8 The aim of this study was to assess the value of raised ACE level in making a clinical diagnosis of ocular sarcoidosis in a group of patients with signs of ocular inflammation compatible with sarcoidosis, in whom tissue biopsy was either not practical or not possible. For this purpose, the ocular manifestations and the extraocular (clinical) course in these patients, known as the presumed ocular sarcoidosis group, were compared with those of a group of patients with ocular inflammation due to biopsy-proven sarcoidosis.
PATIENTS AND METHODS
The hospital records of all patients with ocular inflammatory disease compatible with sarcoidosis attending the uveitis clinics of the Birmingham and Midlands Eye Hospital between 1990 and 1995, were retrospectively reviewed. All patients had raised serum ACE level and no histological proof of lye (1997) 11, 365-370 © 1997 Royal College of Ophthalmologists sarcoidosis. Some of these patients had already been under review for several years in other clinics before they were referred to the uveitis clinic. All patients were under the combined care of an ophthalmologist (P.1.M.) and a physician (D.W.Y.) A total of 22 patients were included in this presumed ocular sarcoidosis group. The mean age (±SD) was 37.1 ± 16.4 years (range 14-87 years); 15 patients were female and 7 male. Information regarding type and duration of intraocular inflamma tion, treatment, initial and latest visual acuity and intraocular operations was recorded. The results of serum ACE, full blood count, VDRL, TPHA, liver function tests (LFT), chest radiograph (CXR) and pulmonary function tests (PFT) were also recorded.
The results of these tests were compared with those in a group of 18 patients, attending the same clinics, with ocular inflammation due to histologically proven sarcoidosis, regardless of serum ACE levels. Of these 18 patients, 12 had positive tissue biopsy and the remainder had a positive K veim test. The mean age (±SD) in this group was 46.1 ± 16.1 years (range 21-75 years). Patient demographics for the two groups are summarised in Table 1 .
The mean follow-up (±SD) for the presumed ocular sarcoidosis group was 4.5 ± 3.4 years (range 0.5-12 years), as compared with 7.8 ± 5.3 years Statistical analysis was performed using the unpaired two-sample t-test (age, follow-up, serum ACE levels) and Wilcoxon rank sum test (sex, race, ocular manifestations).
RESULTS
Age, sex and race distribution were similar in the two groups, while the follow-up was longer in the biopsy proven sarcoidosis group (p = 0.02).
All patients in the presumed ocular sarcoidosis group had raised ACE levels, while serum ACE levels were available in 11 of the 18 patients in the biopsy-proven sarcoidosis group. Of these 11 patients, 8 had raised levels while the remaining 3 had normal levels. The mean ACE levels (SD) were 129 units/l (range 75-290 units/I) for the presumed ocular sarcoidosis group and 157 units/l (range 89-310 units/I) for the biopsy-proven sarcoidosis group. The normal range for ACE in our laboratory is 12-71 units/l for adults and 15-87 units/l for children. No statistically significant difference was found in the mean ACE values in the two groups (p = 0.36).
All 22 patients with presumed ocular sarcoidosis had CXR performed, while 18 patients also had PFT. Of the 22 patients, 11 (50%) had CXR changes compatible with sarcoidosis, 9 patients had bilateral hilar lymphadenopathy (BHL), 1 patient had BHL and parenchymal lung disease and 1 patient had extensive parenchymal lung disease without lympha denopathy. Sixteen of the 18 patients (88.8 %) tested � ad � bnormal P � T of reduced total lung capacity or lffipaIred gas dIffusion, which could be consistent with sarcoidosis. All patients with abnormal CXR had abnormal PFT. In addition, 5 patients with normal CXR had abnormal PFT.
In an attempt for histological proof of sarcoidosis, 3 of the 5 patients with normal CXR and abnormal PFT underwent trans bronchial lung biopsy, which was reported as normal. In patients with abnormal CXR and LFT, no attempt for histological proof of sarcoidosis by trans bronchial lung biopsy was made. � evertheless, tissue biopsy was attempted when mtraocular material was available. In this way, iris granulomata were found on biopsy from a patient who underwent trabeculectomy and who was subse quently moved into the biopsy-proven sarcoidosis group.
. � he ocular manifestations in the two groups were slITlllar and are summarised in Table II. All but 3 patients in the presumed ocular sarcoidosis group and 2 ? atient � in the biopsy-proven sarcoidosis group had bIlateral Involvement. The most common mani festation in the both groups was retinal vasculitis with p � nuveitis, which occurred in 19 patients (86.4 % ) WIth presumed ocular sarcoidosis and in 15 patients (83.3%) with biopsy-proven sarcoidosis. Retinal ne � vascularisation was seen only in one eye of a patlent (5.6%) in the biopsy-proven sarcoidosis group. This patient had two episodes of vitreous haemorrhage due to new vessels on the disc. The neovascularisation regressed after pametinal photo- coagulation and addition of azathioprine to the systemic steroids. Peripheral punched-out chorioretinal lesions were seen in 11 patients (50%) with presumed ocular sarcoidosis and in 12 patients (66.7%) with biopsy proven sarcoidosis. They were more commonly seen in the inferior equatorial area, although rarely they affected the posterior pole.
The medical treatment required to control the intrao . cular inflammation and/or the systemic symp toms In the two groups is summarised in Table III. Eleven of the 22 patients (50%) with presumed o � ular . sarcoidosis and 12 of the 18 patient (67 % ) WIth bIOpsy-proven sarcoidosis required long-term systemic steroids. Two patients with presumed ocular sarcoidosis and 1 patient with biopsy-proven sarcoi dosis required additional immunosuppression (azathioprine) due to failure of systemic steroids or steroid-induced side-effects. Surgical intervention was required in 6 of 44 eyes in the presumed ocular sarcoidosis group and in 9 of 36 eyes in the biopsy proven group. The intraocular procedures performed are documented in Table IV. Severe permanent visual loss (visual acuity <6/60) was noted in 3 of the 44 eyes (6.8 % ) in the presumed These studies have also reported a higher incidence of ocular involvement in black patients, while in this series only 59% of patients in the presumed ocular sarcoidosis group and 39% of patients in the biopsy proven sarcoidosis group were of Afro-Caribbean ongm.
It is also interesting that in this study only 1 patient (5.6%) in the biopsy-proven sarcoidosis group developed retinal neovascularisation, whilst no patient in the presumed ocular sarcoidosis group showed evidence of this complication. This is in contrast to other studies which reported an incidence Severe visual loss of less than 6/60, in uveitis associated with sarcoidosis, varies from 12.5% to 19% and is usually due to chronic macular oedema, glaucoma, epiretinal membrane formation and retinal neovascularisation.
3 , JO , 1l ,26 The relatively low percentage of severe visual loss of 6.8 % in the presumed ocular sarcoidosis group and 5.6% in the biopsy-proven sarcoidosis group in this series may be due to the tertiary nature of our uveitis clinic.
In the presumed ocular sarcoidosis group, 1 of the 3 patients who had an abnormal CXR at presentation did not have radiological evidence of the disease on subsequent tests. His serum ACE had also fallen to normal levels and he was being treated with systemic steroids. In the biopsy-proven sarcoidosis group, 2 of the 5 patients who had an abnormal CXR on presentation also had no radiological evidence of the disease on subsequent tests. The ACE was In this group of patients raised serum ACE was a useful biochemical marker of disease activity. This finding suggests that when a patient is examined for the first time in such a phase it may be difficult to detect any systemic sarcoid abnormalities that may have been present many years earlier.
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Systemic steroids can suppress the inflammatory reaction seen in sarcoidosis and usually cause reduction in the serum ACE levels. In this study, 2 of the 3 patients with biopsy-proven sarcoidosis who had normal ACE levels were on systemic steroids at the time of testing, which may have influenced the results. ACE levels were not available for a number of patients in the biopsy-proven group. This may have been due to these patients being diagnosed many years previously at a time when ACE testing was not in widespread use.
Power et at.14 recently stated that uveitis patients with a raised ACE level and abnormal gallium scan should be considered as having sarcoidosis. They also found a raised ACE level in a small percentage of patients with wide variety of uveitis syndromes not due to sarcoidosis. This differs from our study, where we were only looking at patients whose uveitis was indistinguishable from that seen in patients with biopsy-proven sarcoidosis. It was not our intention to measure ACE levels in every patient attending our uveitis clinics.
In conclusion, the results of this study show that the two groups studied had similar ocular manifesta 
